<DOC>
	<DOC>NCT00131352</DOC>
	<brief_summary>This clinical study is to evaluate the safety and efficacy of hylan G-F 20 (Synvisc) in patients with symptomatic knee osteoarthritis (OA). Patients will be given 6 mL of hylan G-F 20 (Synvisc) (or a phosphate buffered saline control), with a possible repeat treatment with Synvisc after the week 26 visit.</brief_summary>
	<brief_title>A Study of the Safety and Efficacy of Hylan G-F 20 (Synvisc) in Patients With Symptomatic Osteoarthritis of the Knee</brief_title>
	<detailed_description>The trial included an initial 26 week treatment with 6 mL of hylan G-F 20 (Synvisc) (or a phosphate buffered saline control) followed by a 4 week repeat treatment of Synvisc.</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<mesh_term>Musculoskeletal Diseases</mesh_term>
	<mesh_term>Hylan</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Patient with documented diagnosis of primary osteoarthritis (OA) of the target knee made at least 3 months prior to Screening, Has radiographic evidence of OA in the tibiofemoral compartment of the target, knee with at least 1 definite osteophyte and a measureable joint space, as diagnosed by standard Xrays taken not longer than 3 months prior to Screening, and before any baseline assessment, Has continued target knee pain despite conservative treatment (e.g. weight reduction, physical therapy, analgesics), Has pain in the target knee as demonstrated by a score of 2 or 3 on the Western Ontario and McMaster Universities Osteoarthritis Index Likert Scale Version 3.1 (WOMAC LK 3.1) A1 (Walking Pain) Subscale , Has a mean score of 1.5 to 3.5 on the Western Ontario and McMaster Universities Osteoarthritis Index Likert Scale Version 3.1 (WOMAC LK 3.1) A (Pain) Subscale. Inclusion Criteria for Repeat Phase: Must have no major safety concerns during the first course of treatment as assessed by the Investigator; Must have a WOMAC LK 3.1 A score of at least 1. Exclusion criteria: Has modified KellgrenLawrence Numerical Grading System of grade IV in the patellofemoral compartment of the target knee confirmed by standard Xrays taken not longer than 3 months prior to Screening, and before any baseline assessment, Has clinically apparent tense effusion of the target knee, Has had viscosupplementation in any joint including the target knee within 9 months prior to Screening, Has concomitant inflammatory disease or other condition that affects the joints (e.g. rheumatoid arthritis, metabolic bone disease, psoriasis, gout, symptomatic chondrocalcinosis and active infection, etc.,) Symptomatic OA of the contralateral knee or of either hip that is not responsive to paracetamol and requires other therapy, Has related hypersensitivities to avian proteins and/or any components of hyaluronanbased injection devices,</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Osteoarthritis of the knee</keyword>
	<keyword>Musculoskeletal</keyword>
</DOC>